Drug Profile
p27/p16 fusion gene therapy - GPC Biotech
Alternative Names: AV-W9 gene therapy; CDK inhibitor gene therapy - GPC Biotech; Cyclin dependent kinase inhibitor gene therapy - GPC Biotech; p16/27 gene therapy; p27/p16 gene therapyLatest Information Update: 27 Apr 2004
Price :
$50
*
At a glance
- Originator GPC Biotech Inc
- Class
- Mechanism of Action Cyclin-dependent kinase inhibitors; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Vascular restenosis
Most Recent Events
- 27 Apr 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 27 Apr 2004 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
- 14 Nov 2002 p27/p16 gene therapy is available for licensing from GPC Biotech (www.gpc-boiotech.com)